04:16 PM EDT, 05/16/2024 (MT Newswires) -- Amgen's ( AMGN ) Imdelltra received accelerated approval from the US Food and Drug Administration for the treatment of patients with extensive stage small cell lung cancer whose tumors have stopped responding to chemotherapy.

The approval is based on interim results from a study showing Imdelltra reduced tumors in about 40% of patients, the FDA said Thursday in a statement.

Amgen ( AMGN ) did not immediately respond to MT Newswires' request for comment.